JLE

Journal de Pharmacie Clinique

MENU

Estimating productivity losses in medico-economic studies: it's not rocket science Volume 39, issue 4, Décembre 2020

Figures






Tables

Authors
1 Pôle de Santé publique, Service d’évaluation économique en santé, Hospices civils de Lyon, LyonFrance
2 Pôle pharmacie, Service de pharmacie, Grand hôpital de l’Est francilien, MeauxFrance
* Correspondance

Several cost-of-illness studies have shown that productivity losses could represent the largest part of chronic and disabling illness. However, productivity losses are not widely valued in medico-economic valuations (EME) in France. The French national authority for health (HAS) does not recommend to include productivity losses in the cost effectiveness/utility ratios of EME. Nevertheless, it is possible to value productivity losses in a secondary analysis. Lack of necessary data and valuation method consensus to value productivity losses may be reasons for the absence of productivity losses in medico-economic studies. The objective of this article was to support all the stakeholders involved in economic health assessment (physicians, pharmacists, student, etc.) in valuing losses in productivity by providing the information necessary to value these losses through the presentation of methods of evaluation, examples of pathologies with detailed evaluation and the presentation of results in the literature.

Licence This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License